Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to -$9.3 million.

  • Arcturus Therapeutics Holdings' Change in Receivables fell 25134.12% to -$9.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$22.2 million, marking a year-over-year decrease of 17737.19%. This contributed to the annual value of -$28.1 million for FY2024, which is 19587.03% down from last year.
  • Latest data reveals that Arcturus Therapeutics Holdings reported Change in Receivables of -$9.3 million as of Q3 2025, which was down 25134.12% from $2.6 million recorded in Q2 2025.
  • Arcturus Therapeutics Holdings' 5-year Change in Receivables high stood at $89.7 million for Q1 2023, and its period low was -$89.7 million during Q2 2023.
  • Moreover, its 5-year median value for Change in Receivables was -$118000.0 (2021), whereas its average is $306631.6.
  • The largest annual percentage gain for Arcturus Therapeutics Holdings' Change in Receivables in the last 5 years was 2759104.94% (2023), contrasted with its biggest fall of 611080.33% (2023).
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' Change in Receivables stood at $1.4 million in 2021, then tumbled by 46.75% to $720000.0 in 2022, then plummeted by 955.0% to -$6.2 million in 2023, then tumbled by 326.01% to -$26.2 million in 2024, then surged by 64.72% to -$9.3 million in 2025.
  • Its Change in Receivables was -$9.3 million in Q3 2025, compared to $2.6 million in Q2 2025 and $10.6 million in Q1 2025.